Air Premia Expands Fleet with 6th Boeing 787-9 Dreamliner, Plans New Routes for 2025
SEOUL,South Korea,Dec. 20,2024--Air Premia,Korea\'s leading hybrid carrier,today announced the addition of its sixth Boeing 787-9 Dreamliner,marking its first fleet expansion in over 18 months. The a
BEIJING,Dec. 20,2024-- Baijiayun Group Ltd ("Baijiayun" or the "Company") (NASDAQ: RTC),a one-stop AI video solution provider,today announced it\'s "DuanXunBao"has ushere
LAS VEGAS and SEOUL,South Korea,Dec. 21,2024--Gaudio Lab,a leader in AI audio technology,will participate in CES early next year,presenting a range of AI audio solutions across various industries. The
Wrap Up the Holidays with Bedsure Exceptional Discounts
NEW YORK,Dec. 21,2024-- The holiday season has arrived,andBedsure is bringing warmth and coziness to gift-giving with exceptional discounts on a selection of premium products. From luxurious throw bla
SYDNEY,Dec. 20,2024-- Nucleus Software,India\'s leading provider of robust digital lending and transaction banking solutions to the global financial services industry,is pleased to announce the appoi
Shapellx Supports Women in Need with $30,000 Product Donation
ORLANDO,Fla.,Dec. 20,2024--In a heartfelt initiative to spread warmth and hope during the holiday season,the leading shapewear brand Shapellx donated $30,000 value of products to HELP NOW,an organizat
SAN FRANCISCO and SUZHOU,China,Dec. 20,2024-- Innovent Biologics,Inc. ("Innovent") (HKEX: 01801),a world-class biopharmaceutical company that develops,manufactures and commercializes high qu
CPIC: Deepening Presence in the Greater Bay Area to Promote its Connectivity and Integration
SHANGHAI,Dec. 21,2024--In December 2024,China Pacific Insurance Company(CPIC) celebrates the 15th anniversary of its H-share listing.
TCL Zhonghuan ESG Rating Upgraded to BBB by MSCI
SHENZHEN,China,Dec. 20,2024-- On December 16th,Morgan Stanley Capital International (MSCI),a globally recognized financial services firm,has upgraded TCL Zhonghuan\'s ESG rating from "BB" to
SHANGHAI,Dec. 21,2024-- YolTech Therapeutics today announced updated data from its ongoing Phase I/IIa clinical trial of YOLT-201,a first-in-class CRISPR/Cas9-based in vivo gene-editing therapy for AT